Home
NewsNewsCSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
On March 5, 2026, CSG.BIO, which is a global life sciences and healthcare platform with services across fertility, reproductive health, and biologic preservation, as well as family-building, went ahead with the acquisition of Hanabusa IVF, Asian Egg Bank.
Hanabusa IVF, which is based in San Diego, California, is known for its customised fertility care, which includes its unique approach when it comes to mini-IVF along with lower-stimulation treatments. Asian Egg Bank is now one of the leading options for intended parents and fertility clinics to find Asian donor eggs. The two groups together give CSG.BIO a strong platform for reproductive care and donor eggs that is becoming more important in the US and around the world.
The acquisition of Hanabusa IVF, Asian Egg Bank, adds to the present speciality IVF practice of CSG.BIO, the New England Fertility Institute in Stamford, Connecticut. It turns CSG.BIO into a world leader when it comes to reproductive medicine, with cutting-edge clinics located near major domestic as well as international gateways on both coasts. This next phase helps Hanabusa IVF and New England Fertility Institute work together toward a bigger long-term goal – making personalised fertility care more available, establishing internationally connected surrogacy along with third-party reproduction services, and continuing to expand their specialised mini-IVF offering within the large global network of CSG.BIO.
It is well to be noted that the strategic fit is just as crucial to the Asian Egg Bank. Other organisations in the group include CryoChoice and AlphaCord, as well as CellSave. This kind of sync creates real synergy between family-building support and biologic storage along with reproductive services, and it also makes the infrastructure much stronger when it comes to future growth.
“Joining CSG.BIO gives us the opportunity to build on what makes Hanabusa IVF and Asian Egg Bank so distinctive while gaining the strength of a broader global platform,” said Peter Fuzesi, CEO of Hanabusa IVF and Asian Egg Bank. “We see strong alignment between our mission and CSG.BIO’s capabilities across fertility, preservation, and family-building services. This next step allows us to continue advancing personalised care in San Diego while expanding what we can offer patients, intended parents, and partners around the world.”
“We are thrilled to welcome Hanabusa IVF and Asian Egg Bank into the CSG.BIO family,” said Sarah Al-Hajali, CEO of CSG.BIO. “Hanabusa IVF has built an exceptional reputation for thoughtful, patient-centred fertility care, and Asian Egg Bank adds an important and highly specialised donor egg platform to our growing organisation. Together, these additions strengthen our vision for the future of reproductive medicine, family building, and biologic preservation, and we are excited for what lies ahead.”
Provident Healthcare Partners gave Hanabusa IVF and Asian Egg Bank advice on the transaction by helping it go through. Corbel Capital Partners, an independent investment firm that is based in Los Angeles that executes customised structured debt or equity investments in lower-market businesses and works with management to create value, provided the financing for the deal.
A new Ipsos survey commissioned by Fertility Matters Canada finds 49% of Canadians with an opinion support a national baseline for IVF funding support, with backing rising to 59% among those aged 18–34. One in eight Canadians say cost has already forced them or someone close to delay or abandon fertility treatment.
Alpha Controls & Instrumentation Inc. has been selected by FertiTech Canada Inc. as its third-party calibration partner for Nilotech temperature probes. The partnership channels Canadian IVF laboratories and fertility clinics using Nilotech equipment to Alpha Controls for professional, accredited calibration services, while FertiTech continues to handle equipment supply and gas sensor calibration.
In the UK, a Ten Minute Rule Bill has been introduced in the Commons to create a legal right to paid time off for fertility treatment, aiming to standardize access to time‑sensitive appointments and reduce reliance on employer discretion. The proposal seeks House permission to proceed and spotlights workplace rights during Fertility Awareness Week.
Columbia University Fertility Center has achieved the first confirmed pregnancy using an AI-guided sperm recovery method in a man with azoospermia, as detailed in The Lancet. The STAR system combined advanced imaging, microfluidics, and robotics to retrieve two viable sperm, enabling embryo creation after prior failed surgical and manual attempts.
British Columbia's free IVF program exhausts 2025 funding within months of launch. At least one approved clinic stops accepting new applications. Applicants face aging-out risks and must wait until spring 2026 for next funding allocation.
Singapore’s MOH approves 13 additional genetic conditions for testing before embryos are implanted during IVF, enhancing reproductive genetic screening options.
National Health Service-funded IVF in England varies across regions in terms of access, cycle definitions, and eligibility. While Integrated Care Boards follow NICE guidelines, local implementation differs to meet specific population needs. Current policy reviews aim to enhance consistency and ensure continued access to fertility services across England.
